脳腫瘍のACNUに対する感受性—In vitroのSensitivity testの臨床的応用

Anti-tumor Activity of ACNU against Malignant Glioma:clinical application of in vitro sensitivity test of chemotherapeutic agent

I．はじめに

　悪性脳腫瘍の治療には，手術による腫瘍の摘出および放射線治療が一般化されているが，近年，高い脂肪透過性を持ったnitrosourea系抗癌剤の開発により，血液脳関門（以下BBBと略す）に囲まれた特殊な環境にある脳実質内腫瘍に対しても化学療法が有用な手段として認識されつつある．

　われわれは，日本で開発されたACNU〔1-（4-amino-2-methyl-5-pyrimidinyl）methyl-3-（2-chloroethyl）-3-nitrosourea hydrochloride〕を用いて，．数種のgliomacell lineに対する感受性を上調べたところ，株によりその感受性に著しい差のあることが確かめられた^18）．

In vitro sensitivity test of cultured human malignant glioma cells to ACNU[1-(4-amino-2-methy1-5-pyri-midinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydro-chloride] was performed on Falcon 3064 microtest-plate. Early culture cells established from 10 clinical cases were examined by means of this method and the correlation between in vitro response and clinical response of tumor to ACNU was studied.

In microtestplate assay, it was defined as ACNU sensitive when the tumor growth showed more than 60% suppression when tumor was cultured in the medium which contained 40 mcg/ml of ACNU.